Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Surg Clin North Am ; 104(3): 545-556, 2024 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-38677819

RESUMO

Clostridioides difficile colitis is an important source of hospital-acquired diarrhea associated with antibiotic use. Symptoms are profuse watery diarrhea, typically following a course of antibiotics; however, some cases of fulminant disease may manifest with shock, ileus, or megacolon. Nonfulminant colitis is treated with oral fidaxomicin. C difficile colitis has a high potential for recurrence, and recurrent episodes are also treated with fidaxomicin. Bezlotoxumab is another medication that may be used in populations at high risk for further recurrence. Fulminant disease is treated with maximal medical therapy and early surgical consultation. Antibiotic stewardship is critical to preventing C difficile colitis.


Assuntos
Antibacterianos , Clostridioides difficile , Infecções por Clostridium , Colite , Humanos , Infecções por Clostridium/diagnóstico , Infecções por Clostridium/terapia , Antibacterianos/uso terapêutico , Colite/microbiologia , Colite/diagnóstico , Colite/terapia , Fidaxomicina/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA